Hisamitsu Pharmaceutical: Announcements of individual stocks: Announcement of results for the domestic Phase 2 clinical trial of HP-6050 (transdermal sedative).

JPX · Jul 1 14:00

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.